Cargando…
Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
In late 2019, COVID-19 emerged in Wuhan, China. Currently, it is an ongoing global health threat stressing the need for therapeutic compounds. Linking the virus life cycle and its interaction with cell receptors and internal cellular machinery is key to developing therapies based on the control of i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886108/ https://www.ncbi.nlm.nih.gov/pubmed/35242142 http://dx.doi.org/10.3389/fimmu.2022.841459 |
_version_ | 1784660579099607040 |
---|---|
author | Santos, Susana Barata, Pedro Charmier, Adilia Lehmann, Inês Rodrigues, Suzilaine Melosini, Matteo M. Pais, Patrick J. Sousa, André P. Teixeira, Catarina Santos, Inês Rocha, Ana Catarina Baylina, Pilar Fernandes, Ruben |
author_facet | Santos, Susana Barata, Pedro Charmier, Adilia Lehmann, Inês Rodrigues, Suzilaine Melosini, Matteo M. Pais, Patrick J. Sousa, André P. Teixeira, Catarina Santos, Inês Rocha, Ana Catarina Baylina, Pilar Fernandes, Ruben |
author_sort | Santos, Susana |
collection | PubMed |
description | In late 2019, COVID-19 emerged in Wuhan, China. Currently, it is an ongoing global health threat stressing the need for therapeutic compounds. Linking the virus life cycle and its interaction with cell receptors and internal cellular machinery is key to developing therapies based on the control of infectivity and inflammation. In this framework, we evaluate the combination of cannabidiol (CBD), as an anti-inflammatory molecule, and terpenes, by their anti-microbiological properties, in reducing SARS-CoV-2 infectivity. Our group settled six formulations combining CBD and terpenes purified from Cannabis sativa L, Origanum vulgare, and Thymus mastichina. The formulations were analyzed by HPLC and GC-MS and evaluated for virucide and antiviral potential by in vitro studies in alveolar basal epithelial, colon, kidney, and keratinocyte human cell lines. CONCLUSIONS AND IMPACT: We demonstrate the virucide effectiveness of CBD and terpene-based formulations. F2TC reduces the infectivity by 17%, 24%, and 99% for CaCo-2, HaCat, and A549, respectively, and F1TC by 43%, 37%, and 29% for Hek293T, HaCaT, and Caco-2, respectively. To the best of our knowledge, this is the first approach that tackles the combination of CBD with a specific group of terpenes against SARS-CoV-2 in different cell lines. The differential effectiveness of formulations according to the cell line can be relevant to understanding the pattern of virus infectivity and the host inflammation response, and lead to new therapeutic strategies. |
format | Online Article Text |
id | pubmed-8886108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88861082022-03-02 Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy Santos, Susana Barata, Pedro Charmier, Adilia Lehmann, Inês Rodrigues, Suzilaine Melosini, Matteo M. Pais, Patrick J. Sousa, André P. Teixeira, Catarina Santos, Inês Rocha, Ana Catarina Baylina, Pilar Fernandes, Ruben Front Immunol Immunology In late 2019, COVID-19 emerged in Wuhan, China. Currently, it is an ongoing global health threat stressing the need for therapeutic compounds. Linking the virus life cycle and its interaction with cell receptors and internal cellular machinery is key to developing therapies based on the control of infectivity and inflammation. In this framework, we evaluate the combination of cannabidiol (CBD), as an anti-inflammatory molecule, and terpenes, by their anti-microbiological properties, in reducing SARS-CoV-2 infectivity. Our group settled six formulations combining CBD and terpenes purified from Cannabis sativa L, Origanum vulgare, and Thymus mastichina. The formulations were analyzed by HPLC and GC-MS and evaluated for virucide and antiviral potential by in vitro studies in alveolar basal epithelial, colon, kidney, and keratinocyte human cell lines. CONCLUSIONS AND IMPACT: We demonstrate the virucide effectiveness of CBD and terpene-based formulations. F2TC reduces the infectivity by 17%, 24%, and 99% for CaCo-2, HaCat, and A549, respectively, and F1TC by 43%, 37%, and 29% for Hek293T, HaCaT, and Caco-2, respectively. To the best of our knowledge, this is the first approach that tackles the combination of CBD with a specific group of terpenes against SARS-CoV-2 in different cell lines. The differential effectiveness of formulations according to the cell line can be relevant to understanding the pattern of virus infectivity and the host inflammation response, and lead to new therapeutic strategies. Frontiers Media S.A. 2022-02-15 /pmc/articles/PMC8886108/ /pubmed/35242142 http://dx.doi.org/10.3389/fimmu.2022.841459 Text en Copyright © 2022 Santos, Barata, Charmier, Lehmann, Rodrigues, Melosini, Pais, Sousa, Teixeira, Santos, Rocha, Baylina and Fernandes https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Santos, Susana Barata, Pedro Charmier, Adilia Lehmann, Inês Rodrigues, Suzilaine Melosini, Matteo M. Pais, Patrick J. Sousa, André P. Teixeira, Catarina Santos, Inês Rocha, Ana Catarina Baylina, Pilar Fernandes, Ruben Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy |
title | Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy |
title_full | Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy |
title_fullStr | Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy |
title_full_unstemmed | Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy |
title_short | Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy |
title_sort | cannabidiol and terpene formulation reducing sars-cov-2 infectivity tackling a therapeutic strategy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8886108/ https://www.ncbi.nlm.nih.gov/pubmed/35242142 http://dx.doi.org/10.3389/fimmu.2022.841459 |
work_keys_str_mv | AT santossusana cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT baratapedro cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT charmieradilia cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT lehmannines cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT rodriguessuzilaine cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT melosinimatteom cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT paispatrickj cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT sousaandrep cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT teixeiracatarina cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT santosines cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT rochaanacatarina cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT baylinapilar cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy AT fernandesruben cannabidiolandterpeneformulationreducingsarscov2infectivitytacklingatherapeuticstrategy |